Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Venous Thromboembolism 11Neoplasms 9Venous Thrombosis 8Pulmonary Embolism 5Pancreatic Neoplasms 5Thrombosis 4Thromboembolism 4Lymphoma 3Hemorrhage 3Small Cell Lung Carcinoma 2Sarcoma 2Ovarian Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Carcinoma, Non-Small-Cell Lung 2Venous Thormboembolism 1Urinary Bladder Neoplasms 1Thrombocytopenia 1Stroke 1Stomach Neoplasms 1Soft Tissue Neoplasms 1Multiple Myeloma 1Malignant Female Reproductive System Neoplasm 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Liver Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Enoxaparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Venous Thormboembolism × Enoxaparin × Clear all
NCT02706249 2021-07-08

Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients

Dana-Farber Cancer Institute

Phase 2 Completed
50 enrolled 7 charts

Venous Thormboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡